

RECEIVED.  
SECRETARY OF THE

02 AUG 14 PM

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <b>Amgen Inc.</b>			
2. Address <input type="checkbox"/> Check if different than previously reported <b>1300 Eye Street, NW; Suite 470 East</b>			
3. Principal Place of Business (if different from line 2)  City: <b>Washington</b> State/Zip (or Country) <b>DC 20005</b>			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
<b>L. Nicole Antorcha</b>	<b>202/354-6112</b>	<b>nickiea@amgen.com</b>	<b>3867-12</b>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # <b>31560000</b>

**TYPE OF REPORT** 8. Year  Midyear (January 1-June 30) OR  Year End (July 1-December 31)9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report  Termination Date \_11. No Lobbying Activity **INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was:	<b>EXPENSES</b> relating to lobbying activities for this report were:
Less than \$10,000	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <b>\$</b>	\$10,000 or more <input checked="" type="checkbox"/> <b>\$ 1,380,000</b>
Income (nearest \$20,000)	Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING METHOD.</b> Check box to indicate exp accounting method. See instructions for description of
	<input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions
	<input type="checkbox"/> Method B. Reporting amounts under section 6033(b)( Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162(e) of Internal Revenue Code

Signature

Date 8/12/02



Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Medicare Prescription Drug Benefit; Medicare Reimbursement

Implementation of sections 1861(s)(2), 1881(b)(11)(B), and 1833(t)(6) of the Social Security Act

Reimportation of Pharmaceuticals

Reauthorization of the Prescription Drug User Fee Act

**H.R. 4954:** Medicare Modernization and Prescription Drug Act of 2002

**S. 358:** Medicare Prescription Drug and Modernization Act of 2001

**S. 1135:** Medicare Reform Act of 2001

**S. 1899:** Human Cloning Prohibition Act of 2001

**S. 838, H.R. 2887:** Best Pharmaceuticals for Children Act

**S. 215:** Medication Equity and Drug Savings Act

**S. 2244:** Prescription Drug Price Parity for Americans Act

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives

U.S. Senate

Executive Office of the President

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
L. Nicole Antorcha	
Donna Peterson	

19. Interest of each foreign entity in the specific issues listed on line 16 above   Check if None

Signature 

Date 8/12/02



Registrant Name Amgen Client Name \_\_\_\_\_

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City \_\_\_\_\_ State/Zip (or Country) \_\_\_\_\_

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

**ISSUE UPDATE**

24. General lobbying issues previously reported that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution For lobbying activities	Owners percenta client

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, client or affiliated organization

Signature  Date 8/12/02



Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare Prescription Drug Benefit; Medicare Reimbursement  
 Implementation of sections 1861(s)(2), 1881(b)(11)(B), and 1833(t)(6) of the Social Security Act  
 AWP Reform  
 Hospital Outpatient Prospective Payment System (OPPS)

**H.R. 4954:** Medicare Modernization and Prescription Drug Act of 2002

**S. 358:** Medicare Prescription Drug and Modernization Act of 2001

**S. 1135:** Medicare Reform Act of 2001


17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
 U.S. Senate  
 Executive Office of the President  
 Centers for Medicare and Medicaid Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
Judi A. Teske	
Andrew Swire	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date 8/12/02



Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

Corporate Tax Provisions

**S. 2119:** Reversing the Expatriation of Profits Offshore Act


17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above   Check if None

Signature  Date 8/12/02



Registrant Name Amgen Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

**16. Specific lobbying issues**

Patent Issues Relevant to Hatch-Waxman Reform

**S. 812, H.R. 1862:** Greater Access to Affordable Pharmaceuticals Act


**17. House(s) of Congress and Federal agencies contacted**  Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Peter B. Teeley	
Rita E. Norton	
L. Nicole Antorcha	

19. Interest of each foreign entity in the specific issues listed on line 16 above   Check if None

Signature 

Date 8/12/02

